| Cytokine storm DC Fajgenbaum, CH June New England Journal of Medicine 383 (23), 2255-2273, 2020 | 2645 | 2020 |
| International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease DC Fajgenbaum, TS Uldrick, A Bagg, D Frank, D Wu, G Srkalovic, ... Blood, The Journal of the American Society of Hematology 129 (12), 1646-1657, 2017 | 511 | 2017 |
| HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy DC Fajgenbaum, F van Rhee, CS Nabel Blood, The Journal of the American Society of Hematology 123 (19), 2924-2933, 2014 | 359 | 2014 |
| International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease F Van Rhee, P Voorhees, A Dispenzieri, A Fosså, G Srkalovic, M Ide, ... Blood, The Journal of the American Society of Hematology 132 (20), 2115-2124, 2018 | 331 | 2018 |
| Overview of Castleman disease A Dispenzieri, DC Fajgenbaum Blood, The Journal of the American Society of Hematology 135 (16), 1353-1364, 2020 | 317 | 2020 |
| Idiopathic multicentric Castleman's disease: a systematic literature review AY Liu, CS Nabel, BS Finkelman, JR Ruth, R Kurzrock, F van Rhee, ... The Lancet Haematology 3 (4), e163-e175, 2016 | 299 | 2016 |
| Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman disease N Iwaki, DC Fajgenbaum, CS Nabel, Y Gion, E Kondo, M Kawano, ... American Journal of Hematology 91 (2), 220-226, 2016 | 276 | 2016 |
| The full spectrum of Castleman disease: 273 patients studied over 20 years E Oksenhendler, D Boutboul, D Fajgenbaum, A Mirouse, C Fieschi, ... British Journal of Haematology 180 (2), 206-216, 2018 | 184 | 2018 |
| Clinical and pathological characteristics of HIV-and HHV-8–negative Castleman disease LI Yu, M Tu, J Cortes, ZY Xu-Monette, RN Miranda, J Zhang, RZ Orlowski, ... Blood, The Journal of the American Society of Hematology 129 (12), 1658-1668, 2017 | 175 | 2017 |
| International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease F Van Rhee, E Oksenhendler, G Srkalovic, P Voorhees, M Lim, ... Blood advances 4 (23), 6039-6050, 2020 | 136 | 2020 |
| Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease DC Fajgenbaum Blood, The Journal of the American Society of Hematology 132 (22), 2323-2330, 2018 | 136 | 2018 |
| Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease DC Fajgenbaum, RA Langan, AS Japp, HL Partridge, SK Pierson, ... The Journal of clinical investigation 129 (10), 4451-4463, 2019 | 112 | 2019 |
| Castleman disease A Carbone, M Borok, B Damania, A Gloghini, MN Polizzotto, ... Nature Reviews Disease Primers 7 (1), 84, 2021 | 96 | 2021 |
| Castleman disease pathogenesis DC Fajgenbaum, D Shilling Hematology/Oncology Clinics 32 (1), 11-21, 2018 | 93 | 2018 |
| Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate P Mehta, DC Fajgenbaum Current opinion in Rheumatology 33 (5), 419-430, 2021 | 78 | 2021 |
| Plasma proteomics identifies a ‘chemokine storm’in idiopathic multicentric Castleman disease SK Pierson, AJ Stonestrom, D Shilling, J Ruth, CS Nabel, A Singh, Y Ren, ... American journal of hematology 93 (7), 902-912, 2018 | 77 | 2018 |
| Increased mTOR activation in idiopathic multicentric Castleman disease DJ Arenas, K Floess, D Kobrin, RAL Pai, MB Srkalovic, MA Tamakloe, ... Blood, The Journal of the American Society of Hematology 135 (19), 1673-1684, 2020 | 66 | 2020 |
| Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic … Y Nishimura, DC Fajgenbaum, SK Pierson, N Iwaki, A Nishikori, ... American Journal of Hematology 96 (10), 1241-1252, 2021 | 64 | 2021 |
| Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue DC Fajgenbaum, M Rosenbach, F van Rhee, A Nasir, J Reutter JAMA dermatology 149 (2), 204-208, 2013 | 63 | 2013 |
| Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease L Zhang, A Zhao, M Duan, Z Li, X Cao, J Feng, D Zhou, D Zhong, ... Blood, The Journal of the American Society of Hematology 133 (16), 1720-1728, 2019 | 62 | 2019 |
